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A rapid, reliable method for distinguishing tumors or metastases
that overexpress human epidermal growth factor receptor 2 (HER2)
from those that do not is highly desired for individualizing therapy
and predicting prognoses. In vivo imaging methods are available
but not yet in clinical practice; new methodologies improving
speed, sensitivity, and specificity are required.Methods: A HER2-
binding Affibody molecule, ZHER2:342, was recombinantly fused with
a C-terminal selenocysteine-containing tetrapeptide Sel-tag, allow-
ing site-specific labeling with either 11C or 68Ga, followed by bio-
distribution studies with small-animal PET. Dosimetry data for the 2
radiotracers were compared. Imaging of HER2-expressing human
tumor xenografts was performed using the 11C-labeled Affibody
molecule. Results: Both the 11C- and 68Ga-labeled tracers initially
cleared rapidly from the blood, followed by a slower decrease to 4–
5 percentage injected dose per gram of tissue at 1 h. Final retention
in the kidneys was much lower (.5-fold) for the 11C-labeled pro-
tein, and its overall absorbed dose was considerably lower.
11C-ZHER2:342 showed excellent tumor-targeting capability, with
almost 10 percentage injected dose per gram of tissue in HER2-
expressing tumors within 1 h. Specificity was demonstrated by
preblocking binding sites with excess ligand, yielding significantly
reduced radiotracer uptake (P 5 0.002), comparable to uptake in
tumors with low HER2 expression. Conclusion: To our knowl-
edge, the Sel-tagging technique is the first that enables site-
specific 11C-radiolabeling of proteins. Here we present the
finding that, in a favorable combination between radionuclide
half-life and in vivo pharmacokinetics of the Affibody molecules,
11C-labeled Sel-tagged ZHER2:342 can successfully be used for
rapid and repeated PET studies of HER2 expression in tumors.
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Overexpression of the human epidermal growth factor
receptor 2 (HER2), found in about 20%–30% of breast
cancers, is associated with poor prognosis, and HER2 is
the molecular target for effective but expensive monoclonal
antibody drugs such as trastuzumab (Herceptin; Roche) (1).
Determination of the expression levels of HER2 is therefore
important for predicting prognosis and for patient stratifi-
cation for treatment. Currently, expression levels are mainly
determined using biopsies for molecular assays such as in
situ hybridization (2). These procedures are, however, in-
vasive, are difficult to perform repeatedly, and risk missing
overexpressing tissue due to sampling errors. Therefore, the
radionuclide-based in vivo molecular imaging of HER2,
primarily using polypeptide probes, is rapidly expanding,
aiming for personalized medicine with image-and-treat
strategies (3–6). Speed, sensitivity, and specificity are nec-
essary for implementation in clinical routines.
Comparing nuclear medicine imaging techniques, PET has
better spatial resolution, higher sensitivity, and more accurate
quantification than SPECT. With recent radiolabeling advan-
ces, the feasibility of using polypeptides for PET has
increased (4,7,8). Although 18F (energy maximum of emitted
positron [Emax], 0.635 MeV; half-life [t1/2], 109.8 min; 97%
b1-decay) is the PET nuclide most used clinically, the
shorter-lived 11C (Emax, 0.96 MeV; t1/2, 20.4 min; 100%
b1-decay) is also widely used in PET molecular imaging
and in clinical evaluations of a range of cancers (9,10). Its
relatively low positron energy is suitable for high-resolution
imaging. Its short half-life and complete decay by positron
emission give lower radiation doses and allow same-day im-
aging and repeated investigations with either the same or
different radiotracers within a few hours, all of which are
desirable options for longitudinal therapy monitoring. The
in vivo observation of 11C-labeled tracers is limited to about
60–80 min, so they must clear rapidly from nonspecific com-
partments for high-contrast imaging of molecular targets.
Also, the labeling method must be rapid and, for many pro-
teins, avoid denaturing conditions to maintain protein integ-
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rity and target-binding features. The only reported way to
site-specifically label proteins with 11C uses a Sel-tag, a small
tetrapeptide motif containing a selenocysteine residue
(denoted Sec or U) in a C-terminal -Gly-Cys-Sec-Gly se-
quence (11,12). In its oxidized state, the Cys-Sec pair forms
an inert selenenylsulfide. When it is reduced, the Sec
becomes exposed as a highly reactive nucleophile that can
rapidly react with electrophiles such as 11C-methyl iodide
(CH3I) for 11C-labeling (11,12). In this study, we have in-
vestigated the use of this technique to 11C-label an Affibody
molecule (Affibody AB) for HER2 imaging in vivo.
Affibody molecules are highly stable scaffold proteins
derived from staphylococcal protein A (13). By randomiz-
ing 13 surface residues, large libraries of affinity proteins
have been created, from which binders to several different
targets have been selected by various methods (14). Their
small size (58 residues, 6.5 kDa), high thermal and pH
stability, cost-efficient production, and potentially high tar-
get-binding affinity and specificity make them attractive can-
didates for radionuclide-based molecular imaging (15). The
best-characterized Affibody molecule to date has picomolar
affinity to HER2 (16) and has been labeled with, for ex-
ample, 111In, 99mTc, 68Ga, and 18F and successfully used in
preclinical (17) and clinical (18) molecular imaging. Be-
cause Affibody molecules display rapid pharmacokinetics,
are quickly cleared from the circulatory system, and have
a size well below the molecular weight limit for glomerular
filtration, we reasoned that they might be appropriately
labeled with even shorter-lived radionuclides such as 11C.
The HER2 binder ZHER2:342 (16) was used here for 11C-
labeling, and an epidermal growth factor receptor (EGFR)–
targeting Affibody molecule, ZEGFR:2377 (19), was also
included to demonstrate the general applicability of the tag-
ging technique with maintained specificity in target binding.
To compare the pharmacokinetics of the 11C-labeled tracer
with that of previous probes (18,20), ZHER2:342-ST was alter-
natively labeled with 68Ga (Emax, 1.9 MeV; t1/2, 68 min; 89%
b1-decay), a generator-produced positron emitter that is
increasingly being used in nuclear medicine. We present
results that collectively suggest that 11C-labeled Sel-tagged
Affibody molecules may prove highly useful in tumor re-
ceptor–based PET, here exemplified with HER2-expressing
tumors.
MATERIALS AND METHODS
Protein Ligand Production
ZEGFR:2377 (19) and ZHER2:342 (16) were recombinantly fused
with a C-terminal Sel-tag and produced using the methods de-
scribed by Cheng et al. (11). For a detailed description, see the
supplemental materials (available online only at http://jnm.
snmjournals.org). ZHER2:342, intended for in vivo studies, was pro-
duced with and without an N-terminal His6-tag, because His6-tags
may cause undesirable elevated liver uptake (21,22). The phenyl-
arsine oxide Sepharose (GE Healthcare) purification of Sel-tagged
proteins (11,12) was not used here, to avoid in vivo usage of
proteins passed over arsenic-based columns. Consequently, the
proteins used were a mixture of UGA (opal stop codon)-truncated
-GC tagged and Sec-containing full-length -GCUG variants,
where U is Sec (11,12). A schematic representation of the Affi-
body molecule with the C-terminal Sel-tag and its reactions as
used here is depicted in Figure 1.
Fluorescent Labeling of Sel-Tagged Proteins
His6-ZEGFR:2377-ST, His6-ZHER2:342-ST, and ZHER2:342-ST were
site-specifically labeled at the Sec residue with 5-IAF (Invitrogen).
A description of the procedure is provided in the supplemental
materials.
Cell-Binding Analysis Using Fluorescence-Activated
Cell Sorting
To verify retained specific binding of the Affibody molecules to
their respective targets after Sel-tagging and labeling with 5-IAF,
the binding of IAF-labeled His6-ZEGFR:2377-ST, His6-ZHER2:342-
ST, and ZHER2:342-ST was analyzed using fluorescence-activated
cell sorting. A detailed description of cell lines, culture conditions,
and the procedure is provided in the supplemental materials.
Radiolabeling of ZHER2:342-ST
Labeling with 11C. 11C-methane was produced by the 14N
(p,a)11C reaction using a PETtrace cyclotron (GE Healthcare)
and was converted to 11C-CH3I in a gas phase reaction (23) using
a Tracerlab FX C Pro synthesis module (GE Healthcare). The
FIGURE 1. Overview of Sel-tagged Affibody format and its appli-
cations. Schematic representation of Affibody molecule and C-ter-
minal Sel-tag. Randomized positions in binding site of Affibody
scaffold are indicated in blue, and Sel-tag is indicated in 3-letter
code. Sel-tag was used here for labeling with fluorescent 5-IAF,
labeling with 75Se and 11C, and conjugation with maleimide-DOTA
for labeling with 68Ga.
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labeling precursor was trapped in dimethylsulfoxide (0.2 mL) at
room temperature. Lyophilized ZHER2:342-ST (250 mg, 33 nmol)
was dissolved in 150 mL of phosphate-buffered saline and reduced
by the addition of dithiothreitol to a final concentration of 2 mM
and incubated for 30 min at 35C. An aliquot of the 11C-CH3I–
dimethylsulfoxide solution (150 mL) was added to the reaction
mixture. After incubation at 35C for 20–25 min, the labeled
protein was purified by size-exclusion chromatography using a
NAP-5 column (GE Healthcare) preequilibrated with phosphate-
buffered saline. The radiochemical purity and identity were assessed
by radio–high-performance liquid chromatography (HPLC) using
ultraviolet (210 nm) and radioactivity detectors in series and a
Superdex Peptide 10/300 GL column (GE Healthcare) eluted with
phosphate-buffered saline.
Labeling with 68Ga. For labeling with 68Ga, ZHER2:342-ST
was conjugated with the macrocyclic chelator maleimido-mono-
amide-DOTA (Macrocyclics) by targeting the Sel-tag, in analogy
to the previously described method using Cys-containing proteins
(24). The conjugate was purified by reversed-phase HPLC, using
a Reprosil Gold 300 C18 (5 mm, 250 · 10 mm) column, before
analysis by liquid chromatography–mass spectrometry and sub-
sequent lyophilization of the conjugate.
The elution, purification, and preconcentration of 68Ga from the
68Ge/68Ga generator (The Open Joint Stock Company Isotope) were
performed as previously described (25). The labeling was per-
formed similarly to the method of Tolmachev et al. (20). Lyophi-
lized ZHER2:342-ST-DOTA (50 mg, 6.6 nmol) was dissolved in the
68Ga concentrate (150–200 mL), and pH was adjusted to 3.5 using
sodium acetate (1.25 M). The labeling mixture was incubated at
90C for 15 min before purification on NAP-5 and HPLC analysis.
The stability of 68Ga-ZHER2:342-ST-DOTA was assessed by in-
cubation in a 500-fold molar excess of ethylenediaminetetraacetic
acid (EDTA) at room temperature for 60 min before analysis by
radio–instant thin-layer chromatography eluted with 0.2 M citric
acid. As a control, 68Ga-ZHER2:342-ST-DOTA was incubated in
water and analyzed in parallel. Furthermore, the stability of
68Ga-ZHER2:342-ST-DOTA in plasma was investigated by incubat-
ing the protein in murine plasma at 37C for 1 h and subsequently
analyzed by radio–sodium dodecyl sulfate polyacrylamide gel
electrophoresis.
In Vivo Small-Animal PET Studies
Experiments were performed in accordance with national
legislation on laboratory animals’ protection and were approved
by the local ethics committee for animal research. The in vivo
characterizations of the radiotracers were studied using female
severe combined immunodeficiency mice without or with SKOV-
3 or A431 xenografts (high or low levels of HER2, respectively).
Mice were inoculated in the right shoulder by subcutaneous injec-
tion of 107 cells, and the SKOV-3 or A431 xenografts were allowed
to grow for 6 or 2 wk, respectively. The average size of the tumors
at the time of the experiment was 121 6 35 mm3 for SKOV-3 and
2166 256 mm3 for A431 tumors. The mice were anesthetized with
isoflurane (5% initially, and then 1.5% during scans) using Micro-
flex nonrebreather masks (Euthanex Corp.) and kept on heating
beds (37C) during experiments. An aliquot of the radiotracer was
diluted with saline to 200 mL for intravenous (tail vein) injections.
Dynamic PET images were acquired using a microPET Focus120
(CTI Concorde Microsystems), processed with microPET Manager
(CTI Concorde Microsystems) and evaluated using Inveon Research
Workplace (Siemens Medical Solutions) software. Data were col-
lected every second from the time of injection for 1 h and corrected
for randoms, dead time, and decay. Images were reconstructed by
standard 2-dimensional filtered backprojection using a ramp filter
and framed to 6 · 10 s, 10 · 1 min, and 8 · 5 min.
To determine the temporal changes of tracer concentrations,
regions of interest based on postmortem measurements of the
tumor dimensions were drawn on the images. Radioactivity
concentrations (Bq/mL) were calculated by calibrating against
a phantom with a known concentration of radioactivity. Assuming
a tissue density of 1 g/mL, the radioactivity concentrations were
divided by the administered activity to obtain a percentage
injected dose per gram of tissue (%ID/g) derived from regions
of interest. In comparisons between different individuals, normal-
ization for body weight was performed.
Comparative Biodistribution of 11C- and 68Ga-Labeled Sel-
Tagged Affibody Molecules. Biodistributions of 11C-ZHER2:342-ST
and 68Ga-ZHER2:342-ST-DOTAwere compared in severe combined
immunodeficiency mice (n5 2). Mice were injected intravenously
with 11C-ZHER2:342-ST (3–4 MBq, 20 mg [2.7 nmol]) and imaged
for 1 h. After complete decay of 11C (.10 half-lives), the same
mice were injected intravenously with 68Ga-ZHER2:342-ST-DOTA
(7–8 MBq, 3 mg [0.4 nmol]) and imaged for an additional hour.
Dosimetry Calculations. The dose ratio was estimated using the
effective half-lives based on the time–activity curves generated for
the regions of interest in the whole body, liver, and kidneys after
tracer administration. The dose ratio was then combined with
values of absorbed dose per unit-cumulated activity tabulated by
MIRD pamphlet 11 (26). Backscattered radiation was omitted.
Tumor-Targeting Studies. The tumor-targeting capability of
11C-ZHER2:342-ST was investigated in mice with SKOV-3 tumors.
Mice (n 5 8) were injected intravenously with radiotracer (4–8
MBq, 6–26 mg, 0.80–3.4; average, 1.9 nmol) and imaged for 1 h.
To determine specificity of tumor uptake, the same mice were
subcutaneously or intravenously injected with a blocking dose
(250 mg, 33 nmol) of nonradioactive ZHER2:342-ST under main-
tained anesthesia and then allowed to recover. After approximately
1 h, mice were sedated, injected with 11C-ZHER2:342-ST, and im-
aged for 1 h. Mice with A431 xenografts (low HER2 expression
levels) (n 5 4) were injected intravenously with 11C-ZHER2:342-ST
and imaged.
After completed imaging, the mice were euthanized by cervical
dislocation under continued anesthesia, after which urine, blood,
and tissue samples were immediately collected. The tumors were
dissected and snap-frozen for subsequent analysis of HER2 ex-
pression by immunohistochemistry.
Radiotracer Stability. To examine the protein degradation and
excretion of 11C-labeled radiometabolites, the urine and plasma
samples collected after death were precipitated with ice-cold ac-
etone and the insoluble and soluble fractions separated (27).
Briefly, 1 mL of ice-cold acetone was added to the sample (50–
100 mL), stirred in a vortex mixer, incubated at220C for 20 min,
and centrifuged. The supernatant and pellet with low- and high-
molecular-weight compounds, respectively, were separated, and
radioactivity was measured.
Immunohistochemistry
The monoclonal mouse anti-HER2 antibody 2F5 that was used
as the primary antibody for the detection of HER2 by immuno-
histochemistry was kindly provided by Dr. Johan Rockberg.
Excised tumors were fixed in 2% formalin, and staining was
performed as previously described (28).
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Statistical Analysis
Data are expressed as mean values with 95% confidence
intervals using a Student t distribution. To determine significant
differences in tumor uptake between baseline scans and after
blocking with nonlabeled tracer in the same animals, data were
analyzed by a paired 2-tailed t test. For comparison of uptake in
different tumor models, an unpaired 2-tailed t test was used, with
equal variances not assumed. Differences were considered signif-
icant if the P value was less than 0.05.
RESULTS
Receptor Binding of Sel-Tagged Affibody Molecules
Sel-tagged Affibody molecules were labeled with 5-IAF
for cell-binding studies by flow cytometry (Fig. 2). The
HER2-binding Affibody molecules clearly bound to HER2-
overexpressing SKOV-3 and MDA-MB-453 cells, whereas
only low fluorescence was observed with A431 cells having
low HER2 expression levels (Fig. 2, top). The EGFR-binding
Affibody molecule bound to EGFR-expressing A431 cells
but not SKOV-3 or MDA-MB-453 cells (Fig. 2, bottom).
Specificity was also demonstrated by blocking with a 10-fold
excess of nonlabeled protein, which significantly reduced
the cell-associated fluorescence (Fig. 2). Thus, neither the
Sel-tag nor its labeling with 5-IAF disrupted the previously
well-characterized specific high-affinity receptor–binding
capability of these Affibody molecules (16,19). These results
encouraged us to further investigate the efficacy of Sel-
tagged Affibody molecules for receptor-targeted imaging in
vivo.
Sel-Tag Mediated Radiolabeling with 11C and 68Ga
ZHER2:342-ST was site-specifically labeled with 11C and
68Ga for subsequent characterization in vivo. Covalent
labeling with 11C was achieved by reacting the reduced
Sel-tag with 11C-CH3I. Procedures for radiolabeling and
purification over the NAP-5 column were completed within
40–45 min from the end of bombardment and 30 min (;1.5
half-lives) from the addition of 11C-CH3I to the reduced
protein. The yields (decay-corrected) and specific activities
were 5%–15% and 10–30 GBq/mmol, respectively. This
specific activity is consistent with the truncated and unla-
beled protein still being present in the isolated product but
is well within levels previously determined necessary for
imaging tumors with high HER2 expression (29). The
radiochemical purity was greater than 97%, according to
radio-HPLC analysis.
FIGURE 2. Binding and specificity analysis of Sel-tagged, fluorescently labeled Affibody molecules binding to SKOV-3 cells, MDA-MB-
453 cells, and A431 cells. Figure shows HER2-binding ZHER2:342-ST and EGFR-binding H6-ZEGFR:2377-ST without blocking (solid line) and
with blocking with 10 times excess of nonlabeled binder (dotted line) and control cells without staining (dashed line).
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For labeling with 68Ga, the Sel-tag was reacted with
maleimide-DOTA, for subsequent DOTA coordination of
the radiometal. The nonoptimized yield and specific activ-
ities of the 68Ga-labeled protein were 31% and 14 GBq/
mmol, respectively, and the radiochemical purity was 94%
after NAP-5 elution.
68Ga-ZHER2:342-ST-DOTA was subjected to EDTA chal-
lenge and incubation in murine plasma in vitro. Radio-
activity distribution on instant thin-layer chromatography
after EDTA challenge was similar to a control sample in
which 68Ga-ZHER2:342-ST-DOTA had been incubated in wa-
ter, with 90%–95% of radioactivity still associated with the
Affibody molecule (data not shown). Similarly, the only
radioactive peak observed on sodium dodecyl sulfate poly-
acrylamide gel electrophoresis after incubation in plasma
corresponded to intact Affibody molecule, indicating that
the radiometal conjugate was stable over time and that
transchelation to serum proteins or EDTA could be disre-
garded.
In Vivo Characterization
Comparative Biodistribution of 11C- and 68Ga-Labeled
Affibody Molecules. Representative PET images summed
for 0–60 min after injection of the 11C- and 68Ga-labeled
tracers are shown in Figure 3A. Blood radioactivity showed
an initial rapid distribution phase, with radioactivity con-
centrations subsequently decreasing after the first 30 min,
with a half-life of 2 and 6 h for the 11C- and 68Ga-labeled
tracers, respectively (Fig. 3B). One hour after injection, the
radioactivity concentration in blood was 3.9 %ID/g and 4.9
%ID/g, respectively. The largest tissue concentrations of
11C, in the kidneys and liver, were confirmed by ex vivo
measurements, which also revealed concentrations in the
pancreas and lung that were comparable to those in the
liver (Supplemental Fig. 1).
After the initial distribution to the liver, the radioactivity
concentration declined to about twice that in the blood at
60 min. After 30 min, the 68Ga radioactivity cleared from
the liver, with a half-life of 7.4 h, whereas 11C slightly
increased (0.4 %ID/g) during the last 30 min of the scan,
possibly indicating hepatic metabolism of the radiotracer.
In agreement with previous studies of Affibody molecules
(21,30), the radioactivity was primarily excreted via the
kidneys. Residualizing 68Ga accumulated in the kidneys,
increasing by 8 %ID/g during the last 30 min of the scan,
probably because of the reabsorption of the tracer in prox-
imal tubules and subsequent intracellular trapping of the
radiometal. In contrast, the nonresidualizing 11C was more
efficiently cleared, with a t1/2 of 14 min between 10 and
22 min and more slowly thereafter (t1/2, 40 min after
30 min). One hour after injection, the concentration of ra-
dioactivity in the kidneys was 5-fold higher for 68Ga than
for 11C (Fig. 3B). The dose ratio was 4.9, that is, the
absorbed dose from 68Ga is approximately 5 times that
from 11C.
11C Radiometabolite Studies. Analyses of samples taken
after death indicated that most of the radioactivity in
plasma and whole blood was acetone-insoluble, high-
molecular-weight compounds (75% at 40 min), whereas
that in the urine was almost exclusively (.95%) acetone-
soluble, lower-molecular-weight nonprotein compounds.
This finding was supported by liquid chromatography–mass
spectrometry analysis of the collected urine samples, in
which no intact Affibody molecule was detected. Analyses
of the 11C radioactivity in the entire mouse body consis-
tently indicated a decrease of 10%–15% of the injected
dose throughout the PET scan, interpreted as loss of volatile
radiometabolites through exhalation.
Rapid HER2 Imaging in Xenograft-Bearing Mice. The
tumor-targeting capability of 11C-ZHER2:342-ST was investi-
gated in mice carrying SKOV-3 xenografts. The specificity
of tumor uptake was investigated by blocking experiments
performed 2–3 h later in the same animals or by imaging
A431 xenografts, which express lower levels of HER2.
Two representative PET images, summed for 10–60 min,
clearly show the SKOV-3 tumor in the baseline scans (Fig.
4A, left) and a marked reduction in uptake of radioactivity
after blocking (Fig. 4A, middle). The kinetics of radioac-
tivity uptake are shown in the time–activity curves in Fig-
ure 4B. Uptake in nonblocked tumors increased rapidly
during the first 30 min, followed by slower increases, with
a tendency of leveling off at 50–60 min. Tumor uptake was
FIGURE 3. Biodistribution and pharmacoki-
netics of 11C- and 68Ga-labeled ZHER2:342-ST.
(A) Two representative maximum-intensity-pro-
jection PET images summed over 0–60 min of
biodistribution of 11C-ZHER2:342-ST and 68Ga-
ZHER2:342-ST-DOTA. Kidneys and bladder are
indicated by arrows. (B) Time–activity curves
for kinetics of 11C-ZHER2:342-ST ()) and 68Ga-
ZHER2:342-ST-DOTA (no symbol) in blood (solid
line), kidneys (dotted line), and liver (dashed
line). B 5 bladder; K 5 kidneys.
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9.96 1.8 %ID/g (n5 8) at 32.5 min. The biodistribution of
11C-ZHER2:342-ST in tumor-bearing mice was otherwise
similar to that in non–tumor-bearing mice. After blocking
with nonlabeled protein, uptake in the SKOV-3 tumors
plateaued after approximately 30 min. Levels decreased
significantly to 5.0 6 1.3 %ID/g at 1 h (P 5 0.002), in-
dicating that the tumor uptake was HER2-mediated. The
biodistribution in blocked and nonblocked animals was
similar, apart from a slightly slower elimination of radio-
activity to the urine observed in the second experiments,
possibly due to insufficient rehydration between scans
(Supplemental Fig. 1).
A significantly lower uptake of radioactivity was found in
A431 xenografts than in the SKOV-3 tumors (P 5 0.0001)
(Fig. 4A, right) and at a level similar to that in the preblocked
SKOV-3 tumors (Fig. 5). Immunohistochemistry staining
confirmed high HER2 expression in the excised SKOV-3
tumors and moderate expression in the A431 tumors (Fig. 6).
DISCUSSION
The development of imaging methods for detecting HER2-
overexpressing tumors could make considerable contribu-
tions to predicting the prognosis and stratification of patients
for appropriate therapy (3,4). This study suggests that PET
with 11C-labeled HER2-targeting Affibody molecules may
represent a promising step toward development of a method
for specific, rapid, and repetitive monitoring over time of
receptor expression levels in tumors.
In addition to their demonstrated high affinities to specific
targets, the small size of the Affibody molecules gives them
excellent pharmacokinetic properties, with rapid clearance
from the blood and nontarget tissues, making tumor imaging
on the day of injection possible (18). By 11C labeling, dose
exposures could be reduced and repeated investigations fa-
cilitated. It is known that the HER2-targeting Affibody mol-
ecule and the therapeutic monoclonal antibody trastuzumab
bind distinct, nonoverlapping epitopes of HER2 (18,31,32).
An attractive and important application of the Affibody-
mediated HER2 imaging would be monitoring therapeutic
responses to trastuzumab. The speed of the imaging described
here and the lower doses from the 11C-labeled radiotracer
would likely allow for repeated imaging of such a therapeutic
response. However, it was vital that the Sel-tagged Affibody
molecules retained their expected cell-targeting specificities.
As evaluated with fluorescence-activated cell sorting, using
the tagged proteins fluorescently labeled with 5-IAF, we
found that the C-terminal Sel-tag did not disturb the binding
to their target receptors, a prerequisite for the in vivo imaging
experiments.
It was an added advantage that the Sel-tag could be used
to label ZHER2:342 with either 11C or 68Ga for comparison of
the impact of the radionuclide on imaging characteristics
using the same ligand scaffold. Because of the short half-
FIGURE 4. Tumor targeting and its spec-
ificity using 11C-labeled ZHER2:342-ST Affi-
body molecule. (A) Representative
maximum-intensity-projection PET images
summed over 10–60 min of tumor targeting
using 11C-ZHER2:342-ST in mouse carrying
HER2-expressing SKOV-3 xenograft, with-
out blocking (left) and after blocking with
excess of cold tracer (middle), and mouse
carrying A431 tumor with low HER2 ex-
pression (right). Tumors, kidneys, and
bladder are indicated by arrows. (B) Kinet-
ics of tumor uptake in blocked (dashed)
and nonblocked (dotted) tumors are pre-
sented in time–activity curves. Statistical parameters are presented in Figure 5. B 5 bladder; K 5 kidneys; T 5 tumors.
FIGURE 5. In vivo binding specificity of 11C-ZHER2:342-ST in mice
carrying HER2-expressing SKOV-3 tumors and low-expressing
A431 tumors. Tumor uptake of 11C-ZHER2:342-ST was significantly
reduced (P 5 0.002) after blocking of HER2 receptors with cold
tracer and in tumors with low expression of HER2, compared
with nonblocked SKOV-3 tumors. Tumor uptake at 32.5 min is pre-
sented. Significant reductions are marked with asterisks in the figure.
*P , 0.05.
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life of 11C, these comparisons could also be made in the
same animals, further reducing interindividual bias. Both
the 11C- and the 68Ga-labeled tracers displayed rapid initial
and thereafter much slower clearance of remaining radio-
activity from the blood. The main difference observed was
the considerably higher retention of 68Ga in the kidneys.
High renal uptake is a common problem for many radio-
metal-labeled small proteins and peptides (33). Although
this problem may be of less significance for detecting ma-
lignancies when, as in breast cancer, the kidneys are not
a common metastatic site, high kidney uptake can poten-
tially become dose-limiting for longitudinal monitoring
of therapeutic effects. In sharp contrast to the 68Ga-label,
the 11C radioactivity cleared much more rapidly from the
kidneys. In fact, the radioactivity concentration and conse-
quently the absorbed dose in the kidneys at the end of the
scan were among the lowest reported for any HER2-bind-
ing Affibody molecule at that time point. The large differ-
ence in kidney uptake and retention obtained with the 2
tracers is most likely due to a high degree of reabsorption
of the Affibody molecule from the primary urine in the
proximal tubule (34) and subsequent intracellular degrada-
tion and trapping of the residualizing 68Ga-label, whereas
nonresidualizing 11C is cleared quickly. The absorbed dose
in all tissues will furthermore be lower because of the short
half-life of 11C. Furthermore, the lower energy of the pos-
itron emitted by 11C than 68Ga yields higher-resolution
images, thereby improving detection of small lesions.
These observations indicate that 11C-labeled Affibody mol-
ecules have excellent imaging properties and may, in some
settings, display advantages over probes labeled with resi-
dualizing radiometals.
The tumor-targeting capability of 11C-ZHER2:342-ST was
clearly demonstrated in our experiments with mice with
HER2-expressing xenografts. The tumor uptake of 10 %ID/g
allowed unambiguous visualization of the tumors already
after 30 min, suggesting that static imaging 30–40 min
after injection could also be possible in clinical settings.
However, uptake in tumors may also be due to unspecific
uptake and retention effects. Here, because of the short
half-life of 11C, the specificity of tumor uptake could be
probed in the same individual animals. The preadministra-
tion with excess unlabeled protein resulted in a significant
reduction in tumor uptake in the second scan performed
only 3 h later. Had the tumor uptake been largely affected
by unspecific permeability and retention effects, which is
often the case with larger molecules (35), this reduction in
uptake would not have been expected. Moreover, the fact
that the uptake was reduced in the blocking experiment to
levels similar to those in A431 xenografts having low
HER2 expression provided further evidence that the in
vivo uptake of 11C-ZHER2:342-ST was rather specific for
imaging of available HER2 receptors in the tumor tissue.
Some uptake could be seen in both A431 tumors and in
blocked SKOV-3 tumors. This uptake in both tumor types
could potentially be due to a low level of HER2 expression
in the A431 cells detectable by the high-affinity HER2 binder
and an incomplete blockage of receptors in the SKOV-3
tumors with unlabeled tracer. However, the uptake could
also be due to the permeability and retention effects, which
could lead to a certain degree of unspecific uptake in tumors.
The choice of radionuclide is crucial for the utility of all in
vivo radiotracers. With the rapidly expanding use of 18F-
FDG PET for detecting lesions with aberrant metabolic rates
(36), the availability of PET centers with cyclotrons (and
cyclotron-produced radionuclides) has increased, and clini-
cal applications of positron-emitting nuclides have widened.
Although longer-lived radionuclides such as 124I and 89Zr are
being used to label slowly clearing antibodies and fragments
(37), the shorter-lived 18F and, as now shown here, even 11C
may be more appropriate choices for probes with rapid phar-
macokinetics. Rapid radiolabeling procedures, such as the
11C-labeling of the Sel-tag demonstrated here, are enabling
technologies toward their implementation.
Future studies of interest include evaluation of the in
vivo imaging potential of the 11C-labeled, Sel-tagged EGFR-
targeting Affibody molecule described here. Further elabo-
ration of the HER2-targeting Affibody molecules’ ability to
detect fluctuation in HER2 expression, during disease devel-
opment and during different therapeutic protocols, is highly
warranted.
CONCLUSION
Affibody molecules could be Sel-tagged for site-specific
labeling without loss of targeting ability. The favorable phar-
macokinetics of the Affibody molecule in combination with
the short-lived 11C provided a radiotracer with improved char-
acteristics for rapid and repeated imaging of HER2 levels.
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